ArticleBMC biology2025
TPpred-CMvL: prediction of multi-functional therapeutic peptide using contrast multi-view learning.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Peptide language pragmatic analysis and two-stage hierarchical learning framework for therapeutic peptide prediction.BMC biology · 2026Article
- PepPharmaHub: a cloud-based platform integrating multimodel language architectures with curated data resources for therapeutic peptide discovery.BMC biology · 2026Article
- Recent advances in multimodal foundation model-enabled peptide screening and optimization for smart biomaterials and functional tissue engineering.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTherapeutic peptides have become an important direction in drug discovery because of their high targeting and low side effects, and are used to treat many diseases. Peptides are short-chain molecules formed by connecting amino acids through peptide bonds and play key roles in the body. The stability and production costs of peptides are challenges that need to be overcome for their pharmaceutical applications. Researchers have improved the accuracy of therapeutic peptide sequence function predictions by constructing and integrating peptide features from different sources. However, accurately predicting multi-functional therapeutic peptides is challenging due to the limitations of handcrafted feature properties, which are unable to capture the full complexity of biological systems.
resultsIn this study, we introduce a novel method TPpred-CMvL for the prediction of multi-functional therapeutic peptide (MTP) based on a contrastive multi-view learning model. This framework directly integrates semantic information pretraining TAPE from protein large language model and evolutionary information. Subsequently, TPpred-CMvL leverages contrastive multi-view learning to comprehensively capture representations of peptide sequences, thereby enhancing the prediction accuracy of MTPs. We utilized adaptive synthetic sampling and focal loss to address the classification imbalance arising from the long-tailed distribution. The experimental results demonstrate that the proposed method outperforms existing related approaches and exhibits the most advanced performance.
conclusionWe developed a contrast multi-view learning model TPpred-CMvL utilizing sequential semantic information TAPE and evolutionary information PSSM. Compared with existing related methods, this method achieved state-of-the-art performance. Finally, a web server has been established and is accessible at http://bliulab.net/TPpred-CMvL .
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.